RxDoctor Payments Data

Robert Lewis, MD

Internal Medicine · Woodville, MSNPI 1093752115

Payments from drug & device makers

$4,528in general payments, 2019–2025

Across 315 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$832
  • Boehringer Ingelheim$430
  • Lilly USA, LLC$357
  • Pfizer$346
  • Sanofi-aventis U.S. LLC$293
  • plus $931 from 13 others

What the payments were for

  • Food & beverage$4,522100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,528 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$34,373
Medicare patients
112
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban351$164,060
JardianceEmpagliflozin159$152,521
AustedoDeutetrabenazine26$70,127
JanuviaSitagliptin Phosphate110$68,304
MounjaroTirzepatide36$65,755
Tresiba Flextouch U-100Insulin Degludec71$56,507
FarxigaDapagliflozin Propanediol48$37,640
EntrestoSacubitril/Valsartan72$34,031
LinzessLinaclotide57$31,505
OzempicSemaglutide20$30,314
RybelsusSemaglutide22$27,587
XifaxanRifaximin16$26,729
Tresiba Flextouch U-200Insulin Degludec21$23,574
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$21,792
RestasisCyclosporine49$21,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$346$176,906392 claims
Boehringer IngelheimJardiance, Combivent Respimat$430$164,224175 claims
MerckJanuvia, Janumet$266$84,700128 claims
Lilly USA, LLCMounjaro, Trulicity$357$77,29647 claims
Teva Pharmaceuticals USA, Inc.Austedo$21$70,12726 claims
AbbVieLinzess, Restasis, Viberzi$91$58,086118 claims
Novo NordiskOzempic, Rybelsus$832$57,90242 claims
AstraZenecaFarxiga$1,338$37,64048 claims
NovartisEntresto$103$34,03172 claims
Astellas Pharma US IncMyrbetriq$13$9,86611 claims
Johnson & JohnsonXarelto$225$8,40715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Woodville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →